Medicare Part B Payment Boost For Biosimilars A Positive Step But ‘More Must Be Done’

The policy is welcomed by biosimilar stakeholders, but amounts to a relatively small increase. To qualify for the revised payment, a biosimilar must have an average sales price that is less than its reference drug’s ASP and not all do.